Thomas J Kipps1, Graeme Fraser2, Steven E Coutre3, Jennifer R Brown4, Jacqueline C Barrientos5, Paul M Barr6, John C Byrd7, Susan M O'Brien8, Marie-Sarah Dilhuydy9, Peter Hillmen10, Ulrich Jaeger11, Carol Moreno12, Paula Cramer13, Stephan Stilgenbauer14, Asher A Chanan-Khan15, Michelle Mahler16, Mariya Salman16, Karl Eckert17, Isabelle G Solman17, Sriram Balasubramanian16, Mei Cheng17, Anil Londhe16, Joi Ninomoto17, Angela Howes16, Danelle F James17, Michael Hallek13. 1. UC San Diego Moores Cancer Center, La Jolla, CA. Electronic address: tkipps@ucsd.edu. 2. Department of Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada. 3. Division of Hematology, Stanford Cancer Center, Stanford University School of Medicine, Stanford, CA. 4. Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute, Boston, MA. 5. CLL Research and Treatment Program, Northwell Health Cancer Institute, Hempstead, NY. 6. University of Rochester, Rochester, NY. 7. Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH. 8. Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, CA. 9. Hôpital Haut-Lévêque, Pessac, France. 10. University of Leeds, Leeds, UK. 11. Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria. 12. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. 13. Department of Internal Medicine and German CLL Study Group, University of Cologne, Cologne, Germany. 14. Department of Internal Medicine III, University of Ulm, Ulm, Germany. 15. Division of Hematology, Mayo Clinic Cancer Center, Jacksonville, FL. 16. Janssen Research and Development, Horsham, PA. 17. Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA.
Abstract
BACKGROUND: Certain genomic features, such as del(11q), expression of unmutated immunoglobulin heavy-chain variable region (IGHV) gene, or complex karyotype, predict poorer outcomes to chemotherapy in patients with chronic lymphocytic leukemia (CLL). PATIENTS AND METHODS: We examined the pooled long-term follow-up data from PCYC-1115 (RESONATE-2), PCYC-1112 (RESONATE), and CLL3001 (HELIOS), comprising a total of 1238 subjects, to determine the prognostic significance of these markers in patients treated with ibrutinib. RESULTS: With a median follow-up of 47 months, ibrutinib-treated patients had longer progression-free survival (PFS) than patients treated in the comparator arm, regardless of genomic risk factors. Among patients treated with ibrutinib, we found that high-risk genomic features were not associated with shorter PFS (63-75% across all subgroups at 42 months) or overall survival (79-83% across all subgroups at 42 months). Surprisingly, we observed that ibrutinib-treated patients with del(11q) actually had a significantly longer PFS than ibrutinib-treated patients without del(11q) (42-month PFS rate 70% vs. 65%, P = .02). CONCLUSION: These analyses not only demonstrate that genomic risk factors previously associated with poor outcomes lose their adverse prognostic significance but also that del(11q) can be associated with a superior PFS with ibrutinib therapy.
BACKGROUND: Certain genomic features, such as del(11q), expression of unmutated immunoglobulin heavy-chain variable region (IGHV) gene, or complex karyotype, predict poorer outcomes to chemotherapy in patients with chronic lymphocytic leukemia (CLL). PATIENTS AND METHODS: We examined the pooled long-term follow-up data from PCYC-1115 (RESONATE-2), PCYC-1112 (RESONATE), and CLL3001 (HELIOS), comprising a total of 1238 subjects, to determine the prognostic significance of these markers in patients treated with ibrutinib. RESULTS: With a median follow-up of 47 months, ibrutinib-treated patients had longer progression-free survival (PFS) than patients treated in the comparator arm, regardless of genomic risk factors. Among patients treated with ibrutinib, we found that high-risk genomic features were not associated with shorter PFS (63-75% across all subgroups at 42 months) or overall survival (79-83% across all subgroups at 42 months). Surprisingly, we observed that ibrutinib-treated patients with del(11q) actually had a significantly longer PFS than ibrutinib-treated patients without del(11q) (42-month PFS rate 70% vs. 65%, P = .02). CONCLUSION: These analyses not only demonstrate that genomic risk factors previously associated with poor outcomes lose their adverse prognostic significance but also that del(11q) can be associated with a superior PFS with ibrutinib therapy.
Authors: Jeff P Sharman; Miklos Egyed; Wojciech Jurczak; Alan Skarbnik; John M Pagel; Ian W Flinn; Manali Kamdar; Talha Munir; Renata Walewska; Gillian Corbett; Laura Maria Fogliatto; Yair Herishanu; Versha Banerji; Steven Coutre; George Follows; Patricia Walker; Karin Karlsson; Paolo Ghia; Ann Janssens; Florence Cymbalista; Jennifer A Woyach; Gilles Salles; William G Wierda; Raquel Izumi; Veerendra Munugalavadla; Priti Patel; Min Hui Wang; Sofia Wong; John C Byrd Journal: Lancet Date: 2020-04-18 Impact factor: 79.321
Authors: Sophie A Herbst; Mattias Vesterlund; Alexander J Helmboldt; Rozbeh Jafari; Ioannis Siavelis; Matthias Stahl; Eva C Schitter; Nora Liebers; Berit J Brinkmann; Felix Czernilofsky; Tobias Roider; Peter-Martin Bruch; Murat Iskar; Adam Kittai; Ying Huang; Junyan Lu; Sarah Richter; Georgios Mermelekas; Husen Muhammad Umer; Mareike Knoll; Carolin Kolb; Angela Lenze; Xiaofang Cao; Cecilia Österholm; Linus Wahnschaffe; Carmen Herling; Sebastian Scheinost; Matthias Ganzinger; Larry Mansouri; Katharina Kriegsmann; Mark Kriegsmann; Simon Anders; Marc Zapatka; Giovanni Del Poeta; Antonella Zucchetto; Riccardo Bomben; Valter Gattei; Peter Dreger; Jennifer Woyach; Marco Herling; Carsten Müller-Tidow; Richard Rosenquist; Stephan Stilgenbauer; Thorsten Zenz; Wolfgang Huber; Eugen Tausch; Janne Lehtiö; Sascha Dietrich Journal: Nat Commun Date: 2022-10-20 Impact factor: 17.694
Authors: John C Byrd; Peter Hillmen; Paolo Ghia; Arnon P Kater; Asher Chanan-Khan; Richard R Furman; Susan O'Brien; Mustafa Nuri Yenerel; Arpad Illés; Neil Kay; Jose A Garcia-Marco; Anthony Mato; Javier Pinilla-Ibarz; John F Seymour; Stephane Lepretre; Stephan Stilgenbauer; Tadeusz Robak; Wayne Rothbaum; Raquel Izumi; Ahmed Hamdy; Priti Patel; Kara Higgins; Sophia Sohoni; Wojciech Jurczak Journal: J Clin Oncol Date: 2021-07-26 Impact factor: 44.544
Authors: Claudia Pérez-Carretero; Isabel González-Gascón-Y-Marín; Ana E Rodríguez-Vicente; Miguel Quijada-Álamo; José-Ángel Hernández-Rivas; María Hernández-Sánchez; Jesús María Hernández-Rivas Journal: Diagnostics (Basel) Date: 2021-05-10
Authors: Miguel Quijada-Álamo; María Hernández-Sánchez; Verónica Alonso-Pérez; Ana E Rodríguez-Vicente; Ignacio García-Tuñón; Marta Martín-Izquierdo; Jesús María Hernández-Sánchez; Ana B Herrero; José María Bastida; Laura San Segundo; Michaela Gruber; Juan Luis García; Shanye Yin; Elisa Ten Hacken; Rocío Benito; José Luis Ordóñez; Catherine J Wu; Jesús María Hernández-Rivas Journal: Leukemia Date: 2020-01-23 Impact factor: 11.528
Authors: Antonello Sica; Caterina Sagnelli; Alfonso Papa; Massimo Ciccozzi; Evangelista Sagnelli; Armando Calogero; Erika Martinelli; Beniamino Casale Journal: Int J Environ Res Public Health Date: 2020-03-16 Impact factor: 3.390
Authors: Lina van der Straten; Paul J Hengeveld; Arnon P Kater; Anton W Langerak; Mark-David Levin Journal: Front Oncol Date: 2021-12-09 Impact factor: 6.244